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A B S T R A C T
Single-domain antibodies (sdAbs) derived from heavy-chain only antibodies produced in camelids are
attractive immunoreagents due to their small size, high afﬁnity, and ability to refold and retain binding
activity after denaturation. It has been observed that some sdAbs, however, exhibit undesirable
properties including reduced solubility when subjected to heating or upon long-term storage at
production-relevant concentrations, which can limit their usefulness. Using a multi-step, rational design
approach that included consensus-sequence driven sequence repairs, the alteration of net protein charge,
and the introduction of non-native disulﬁde bonds, augmented solubility and increased melting
temperatures were achieved. The improved sdAbs tolerated storage in solution at high concentration
(10 mg/mL) and were able to withstand multiple cycles of heating to high temperature (70 C). This work
demonstrates a pathway for improving the biophysical characteristics of sdAbs which is essential for
expanding their utility for both diagnostic as well as therapeutic applications.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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There is an ongoing need for the development of robust
recognitionreagentsforthe sensitive detection ofpotentialbiothreat
agents as well as new and emerging pathogens. Traditionally,
biosensors utilizing antibody recognition elements have provided
reliable detection capability for a broad range of targets; however,
antibodies are prone to failurewhen exposed to harsh environments.
Recombinantly-expressed binding domains derived from the
remarkable heavy-chain-only antibodies produced by camelids
(such as camels and llamas), termed single-domain antibodies
(sdAbs), offer alternative binding elements. sdAbs provide the
afﬁnity and speciﬁcity of traditional antibodies, as well as additional
desirable properties [1–4]. Importantly, many sdAbs have been
demonstrated to refold into an active form able to bind antigen
after heating to high temperatures [5–7]. Additionally, their small
size (1/10 that of conventional antibodies), ability to bind “hidden”
epitopes by virtue of an extended CDR3 region, and ability to
be rationally-selected and produced in quantity by standard$ This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-No Derivative Works License, which
permits non-commercial use, distribution, and reproduction in any medium,
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sdAbs attractive immunoreagents [1–4].
Unlike traditional antibodies, which normally aggregate and
lose their ability to function after being heated above their melting
temperature (Tm; the temperature at which half the protein is
unfolded) [8], sdAbs are often found to recover their binding ability
even after repeated thermal denaturation [5,7]. However, when
heated above their melting temperature at high concentration
and for extended periods of time, many sdAb clones are prone to
aggregation [9]. As aggregation is also a problem with scFvs,
recombinant binding domains derived from conventional anti-
bodies, several strategies have been reported that led to more
soluble and stable recombinant antibody-binding domains (rAbs).
One successful strategy has been to produce sdAbs as fusions with
a thermostable protein, as demonstrated by a fusion between a
sdAb and a thermostable maltose binding protein that was able to
withstand heating to 70 C for an hour without loss of activity [10].
Increasing the net charge of the protein also can lead to more
soluble rAbs. This can be accomplished by either appending a
charged tail onto the rAb [9] or the substitution of charged amino
acids in the protein sequence [11–16].
Researchers have also investigated schemes to increase the Tm
of rAbs. For example, the Tm of a sdAb was increased through the
process of random mutagenesis coupled with a stringent selection,
which led to a 7 C increase in Tm to 90 C [17]. Grafting theC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CDRs) onto a more stable rAb framework has also provided
increases in Tm and stability [18–21]. Finally, the introduction of a
pair of cysteine residues in frameworks 2 and 3 of sdAbs is another
method that has yielded sdAb variants with higher Tms [22–25].
Although most sdAbs are already more soluble and thermally
stable than conventional antibodies or their recombinantly
expressed binding domains (i.e., scFv), enhancing the ability of
sdAbs to retain binding activity after a heat challenge is a useful
metric towards the goal of improving the performance of ﬁeld
portable detection devices in austere environments. To accomplish
this metric, we started with previously described high-afﬁnity
sdAbs speciﬁc for three distinct epitopes on ricin [26,27], and
implemented a multi-step process for obtaining binders with
improved melting temperature and solubility. Ricin is a potent
toxin listed as a select agent by the CDC, and the ability to detect
ricin remains a high priority [28–31]. The potential offered by these
thermal stabilized sdAb reagents to eliminate the cold-chain
makes them a highly attractive alternative to conventional
monoclonal antibody and scFv binding reagents. These sdAbs
have the potential to provide more consistent function, while their
ease of production could make their production less costly than
conventional antibodies. Demonstrating excellent thermostability
is the ﬁrst step towards eliminating the need for refrigeration
of these reagents – a big plus for forward-based troops or
ﬁrst-responders who could then keep their detection reagents
at ambient temperature without negatively impacting shelf-life.
2. Materials and methods
2.1. Reagents
Ricin was purchased from Vector Laboratories. The reagents
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride
(EDC), N-hydroxysulfosuccinimide (sulfo-NHS), and NHS-LC-LC-
biotin were purchased from Pierce. Anti-ricin sdAbs were
described previously [26,27]. Enzymes used for cloning were from
New England Biolabs. DNA sequencing services were provided by
Euroﬁns Genomics. Oligos were also purchased from Euroﬁns
Genomics. Mutagenesis was carried out using the QuickChange
Site Directed Mutagenesis Kit or QuikChange Multi Site-Directed
Mutagenesis Kit from Agilent Technologies. Sequence alignments
were performed using MultAlin [32]. Unless otherwise speciﬁed,
chemical reagents were from Sigma Aldrich, Fisher Scientiﬁc, or
VWR International.
2.2. Selection
Additional ricin clones were selected from our previously
described immune library using essentially the same protocol
previously employed [26]. Two rounds of panning were performed,
and then binding phage were identiﬁed by monoclonal phage
ELISA as described previously [26].
2.3. Introduction of negatively charged amino acids
Negatively charged amino acids were introduced into the
sequences for C10, D12f, and H1W by multisite-directed mutagen-
esis using the following primers (50–30): GGAGGATTGGTGCAG-
GATGGGGGCTCTCTGAGA, AGGATATCGTATGCGGATTCCGTGAAGG-
GCCGA, and AGCGACAACTGGAAGAACACGGTGTATCTGCAA (C10);
GTCACAGACTATGCAGATTCCGTGAAGGGTCGA and GCTAGTAGAA-
ACTCGGATGACTATGGTTACTGG (D12f); and GGAGGATTGGCGCAG-
GATGGGGGTTCTCTCCGA and CAGGCTCCAGGGAAGGAACGTGAG-
TTTGTGGCT (H1W). Mutagenesis reactions were carried out as
described in the product protocol and mutants were identiﬁed and
conﬁrmed by DNA sequencing.2.4. Introduction of additional disulﬁde bond
The introduction of an additional disulﬁde bond in each of the
sdAbs was accomplished by site-directed mutagenesis using the
following primers and their reverse complements: GAGCGT-
GAATTTGTCTGCGTTATTAGTGGTTCT and AAGGGTCGATTCACCTG-
CTCCAGAGACGTCGCC (D12neg), GAACGTGAGTTTGTGTGCGCAAT-
TAGGGCGAGA and AAGGGGCGATTCACCTGCTCCAGAGACAACGGC
(H1Wneg), and GAGCGTGAGTTTGTTTGCGCACTTCGGTGGACT and
AAGGGCCGATTCACCTGCTCCAGCGACAACTGG (C10neg). Following
mutagenesis, the presence of an additional pair of cysteines was
conﬁrmed by sequencing.
2.5. Protein production
A PCR strategy was utilized to remove the upper hinge
sequence; the sdAbs were cloned into pet22b for expression in
the periplasm [33]. Bacteria were grown and protein puriﬁed as
described [9,17]. Brieﬂy, protein was puriﬁed through immobilized
metal afﬁnity chromatography and size exclusion. Protein
concentration was determined by absorbance at 280 nm on a
NanoDrop spectrophotometer.
2.6. Fluorescence based melting assay
The ﬂuorescence based melting assay was conducted using an
Applied Biosystems StepOne Real-Time PCR system and Sypro
Orange dye (Sigma) [33]. A total of 10 mg of each puriﬁed sdAb
was addedto a 20 mL volume of PBS buffer. The Sypro Orange dyewas
diluted 1000-fold into each reaction solution. The temperature was
increased from 25 to 99 C at a rate of 1.2 C/min. All measurements
were done in triplicate and the values agreed within 0.6 C.
2.7. Tm determination by circular dichroism
Refolding and melting temperatures were assessed using a
Jasco J-815 circular dichroism (CD) spectrometer [33,34]. Samples
were diluted with deionized water to a ﬁnal concentration of
40 mg/mL. The differential absorbance of the protein sample was
measured at 205 nm to monitor the secondary structure of the
protein as the temperature was increased from 25 to 90 C
incrementally at a rate of 2.5 C/min. The melting point correlated
to the temperature at the inﬂection point between the folded and
unfolded state. Ellipticity was recorded as samples were cooled to
determine the refolding ability. The error on the Tm determinations
was within 1 C.
2.8. Evaluation of aggregation
To evaluate the degree of aggregation, sdAbs were prepared at
a concentration of 1.0 mg/mL (as measured by OD280 using a
NanoDrop spectrophotometer) in PBS and incubated for 1 h at a
range of temperatures (25, 57, 72, and 87 C). A second experiment
to determine the degree of aggregation resulting from thermal
cycling was performed by preparing sdAbs at a concentration of
1.0 mg/mL and then subjecting them to 10 cycles of heating to 70 C
for 30 min followed by cooling to 25 C for 30 min. Following
incubation or thermal cycling, samples were centrifuged to pellet
any precipitated protein and the concentration was measured
again on the NanoDrop to quantify remaining soluble protein.
2.9. Surface plasmon resonance (SPR)
A BioRad ProteOn XPR36 system and standard GLC sensor chip
was used to assess binding kinetics. Ricin was immobilized to the
sensor chip surface on four rows at a saturating concentration of
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activated surface for 300 s at a ﬂow rate of 30 mL/min. The surface
was inactivated with ethanolamine. To determine binding kinetics,
the chip was turned 90, then 3-fold dilutions (300–0 nM) of each
sdAb were ﬂowed across the chip for 90 or 120 s at 100 mL/min and
binding was recorded on the ricin-coated lanes; next, the buffer
was ﬂowed over for 600 s and the dissociation monitored. The
surface was regenerated with either 50 mM glycine (pH 2.5) or 1%
phosphoric acid between individual samples. The one shot kinetics
was determined from each of the ricin-coated rows using ﬁve
concentrations of single-domain antibody. Kinetic parameters
were calculated using the ProteOn Manager RM 2.1 software. The
average values determined are shown in Table 1. The range of
values from the four measurements was always within a factor of 2,
and typically the four values were within 20%.
2.10. MAGPIX
Sandwich assays were used to characterize the utility of the
thermal stabilized sdAbs for the detection of ricin, and were
performed similar to assays described previously [34,35], however
with an ampliﬁcation step [36]. The sdAbs (1 mg/mL) were
immobilized to MagPlex beads covalently using EDC/NHS reagents
and the standard two step protocol provided by the manufacturer.
The sdAbs were also biotinylated (Bt) using a 5 concentration
sulfo NHS-LC-LC-biotin (Pierce) reagent. Free biotin was removed
using Zeba spin 7K desalting columns (Thermo).
The anti-ricin sdAb-coated microspheres were added to ricin
dilutions prepared in PBST with 1% BSA (PBSTB) in vertical columns
of a 96 well polypropylene round bottom microtiter plate. PBSTB
was used for all reagent dilutions and PBST for the wash steps.
After a 30 min incubation at room temperature in the dark,
unbound ricin was removed by placing the plate on a 96f magnet
(BioTek) and washing three times. The microsphere were then
resuspended in PBSTB and distributed into a different vertical
column for each Bt-sdAb detection antibody to be tested. The
Bt-sdAb (2 mg/mL ﬁnal) was added to each well of its column.
After a 30 min incubation the plate was washed three times to
remove unbound Bt-sdAb. To complete the ampliﬁed ﬂuorescentTable 1
Tm and binding kinetics and afﬁnity characteristics of sdAb clones.
Clone Tm(C), dye melt Tm(C), CD 
C2 65 nd 
C8 58 60 
D12 74 76 
E9 55 58 
H3 53 57 
H1 65 65 
F8 58 59 
D1 50 49 
F11 50 54 
D12f 74 78 
H1W 70 71 
C10 60 66 
D12fneg 77 79 
H1Wneg 62 65 
C10neg 65 65 
D12fneg+ 77 82 
H1W+ 75 78 
H1Wneg+ 68 75 
C10neg+ 78 78 
nd: not done.sandwich assay, a streptavidin conjugated phycoerythrin (SAPE,
Columbia Biosciences) was used as the reporter at a concentration
of 2.5 mg/mL for 15 min, followed by Bt-goat anti-streptavidin
(1 mg/mL, Vector Labs) for 15 min, and a ﬁnal incubation with SAPE
as before, with three washes in between and afterwards. The
microspheres were resuspended in 75 mL of PBST and evaluated on
the MAGPIX instrument (Luminex). Binding was measured from
greater than 50 beads; the error of the mean ﬂuorescence intensity
(MFI) was found to be 5% or less. The sandwich assays were
performed on at least two different days, and in each case, the
experimental data replicated.
3. Results and discussion
3.1. Identifying starting sequences
3.1.1. Evaluation of Tms of high afﬁnity sdAbs isolated in original
library panning
When we originally isolated ricin binders from a phage-display
library derived from two llamas that had been immunized with
ricin toxoid, we found several sequence families, each containing
multiple members [26]. Members of each sequence family shared
sequence homology through their CDR regions (Fig. 1A) and
competed with each other for binding to toxin, indicating a
common epitope among family members. We prepared many of
the identiﬁed proteins for evaluation of their binding kinetics then
chose representatives of three families that showed excellent
afﬁnity and that bound to distinct epitopes on ricin (epitopes 1, 2,
and 3) to more fully characterize and to integrate into assays for
ricin detection [27]. Although family members may share very
similar sequences, it has been observed with sdAbs speciﬁc to
other targets such as Bacillus anthracis and the bacteriophage
MS2 that small changes in sequence can result in major differences
in Tms [34,37]. We therefore started our mission to engineer
anti-ricin sdAbs that possess high Tms and resist aggregation by
re-visiting the previously identiﬁed binders. We used an easily
multiplexed dye-based ﬂuorescent melt assay to provide a ﬁrst
estimate of melting temperature followed by CD which provided
our standard Tm value (Table 1).ka (1/Ms) kd (1/s) KD(M)
1.5 x 109 2.9 x 104 1.9 x 109
1.0 x 106 2.8 x 104 2.7 x 1010
1.9 x 105 1.7 x 104 9.0 x 1010
3.6 x 105 6.1 x 105 1.7 x 1010
4.3 x 105 9.7 x 105 2.2 x 1010
6.4 104 3.9  105 6.1 1010
3.6  105 4.9  105 1.4 1010
4.1 105 3.3 104 8.0  1010
1.3  105 1.2  104 9.0  1010
1.4  106 6.7  105 5.1 1011
2.7  105 1.5 104 5.8  1010
1.3  105 6.1 104 4.9  109
1.7  106 6.9  105 4.1 1011
4.6  105 2.8  104 6.2  1010
2.1 106 1.3  104 6.0  1011
4.8  105 7.3  105 1.5 1010
4.8  105 2.1 103 4.3  109
1.6  106 5.1 103 3.2  109
8.0  105 3.4 104 4.2  1010
Fig. 1. Deduced amino acid sequence of mutants. (A) Sequences from original panning. Three sequence families bind to three epitopes. E9 through D12 bind to epitope 1;
H1 and F8 bind to epitope 2; D1 and F11 bind to epitope 3. The 4 framework (FW) and 3 CDR regions have been labeled and are indicated by green (FW) and blue (CDR) bars
above the sequences. (B) Sequences of D12f, H1W, and C10. The sites of the mutations in D12f and H1W are highlighted by the purple and maroon arrows, respectively. CDRs
are indicated by a blue line. (C) Sequence of negative mutants. Red residues were mutated to the amino acid shown in parenthesis. CDRs are indicated by the blue line below
the sequence. The pI of the original mutant and the “neg” variant are above each sequence. Positions show in orange, and underlined were mutated to C in constructs designed
to have an additional disulﬁde.
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the families. We identiﬁed D12 (Tm 76 C) and H1 (Tm 65 C), which
bind to epitopes 1 and 2, respectively, as potential starting
sequences for designing sdAbs with improved characteristics.
Both members of the third family recognizing epitope 3 (sdAb F11
and D1), however, possessed very low Tms of 54 and 49 C,
respectively.
3.1.2. Additional selections to identify clones with higher Tms
Going back to the immune library and performing additional
selections offered another route for identifying sequences of
ricin-binding sdAbs to serve as starting points for antibody
engineering. This panning did not lead to identiﬁcation of new
sequence families, but new members of the existing families were
selected and their Tm determined. One of the new clones (C10) is in
the same family as the low Tm binders F11 and D1 that binds to
epitope 3 (Fig. 1B). Clone C10, however, was found to have a Tm
over 10 C degrees higher than the other two members of this
family. Therefore clone C10 was identiﬁed as a potential starting
sequence of a sdAb recognizing epitope 3.
3.2. Engineering to optimize based on consensus sequence analysis
The D12 sdAb, which binds to epitope 1 on ricin, possessed the
highest Tm of its family; however, analysis of its sequence revealed
an unpaired Cys in CDR 2. This was reﬂected in the observation of
a sizable dimer peak on puriﬁcation by size-exclusion chromato-
graphy (Supplemental Fig. 1). Other family members have a Ser at
that sequence position; therefore site-directed mutagenesis was
utilized to make the Cys to Ser change. The resultant “ﬁxed” clone,
termed D12f, was found to have the same high afﬁnity as the
parental sequence, and the Tmwas 2 C higher, 78 C as determined
by CD. Even more importantly, the yield improved as only the
desired monomer product was now produced.
Analyzing the sequence of H1, a sdAb that binds to epitope 2,
revealed that in framework 4, an Arg had replace the Trp that isnearly universally conserved among the heavy chains found in rAbs
[38]. Restoring the consensus sequence Trp creating clone H1W,
resulted in a 5 C increase in Tm to 71 C, without decreasing
afﬁnity for ricin or altering the yield.
Epitope 3 binder D1 had a low Tm and an apparent deletion at
the end of CDR2 compared to the consensus sequence [38]. Prior
to isolating C10, a version of D1 was synthesized that restored
the three missing amino acids (Val-Lys-Gly) typically present
at the end of CDR 2. The insertion by itself did not raise the 50 C
Tm of D1. Interestingly sdAb C10, isolated through a new
panning, restored the deletion, among other changes, and melted
at 66 C.
3.3. Negative mutations to improve solubility and aggregation
resistance
Calculation of the isoelectric point (pI) of the three candidate
sequences, D12f, H1W, and C10 produced values of 8.08, 6.64, and
8.65, respectively. We observed that when D12f and C10 were
produced and puriﬁed at concentrations in excess of 5 mg/L they
aggregated and precipitated upon storage in PBS at 4 C. While
these aggregates were reversible upon decreasing the pH of the
solution, this poor solubility at neutral pH was clearly an
undesirable property for either large scale production or during
application. H1W, which has a more negative pI, had no apparent
solubility issues. In addition, when examined by CD, D12f, H1W,
and C10 all show an ability to refold after melting; however, none
of these sdAbs refolded 100% (top panels Fig. 2). This suggested
that even at the dilute concentrations used in CD measurements,
when heated to 95 C, a percentage of the sdAb preparation
was unable to regain its secondary structure, perhaps due to
aggregation. Solutions of the D12f, H1W and C10 sdAbs at a
concentration of 1 mg/mL were subjected to heating to elevated
temperatures, even in excess of their Tm. After heating, the sdAbs
were centrifuged and protein concentration estimated by the
absorbance at 280 nm. As shown in Fig. 3A, the H1W concentration
Fig. 2. CD showing Tm and ability of sdAbs to refold. The top panel shows H1W, C10, and D12f which all show some refolding ability, but none regain 100% of its secondary
structure. The bottom panels show the negative mutants which all show almost perfect refolding after being heated to 95 C.
Fig. 3. Aggregation resistance and activity of sdAbs upon incubation at elevated
temperatures. (A) The sdAbs were prepared at a concentration of  1 mg/mL, and
incubated for 1 h at the indicated temperatures. Following incubation, samples
were centrifuged to pellet any precipitated protein, and the ﬁnal absorbance was
measured, as above. (B) The percentage of binding activity remaining after
incubation at 72 C (for C10, C10neg, H1W, and H1Wneg) or 87 C (for D12f
and D12fneg) as described in (A) was determined. Activity was measured in a
direct-binding format to ricin immobilized on MagPlex microspheres. Dilutions of
each sdAb were added to the MagPlex beads followed by addition of an anti-His tag
IgG – R-phycoerythrin (1 mg/mL) for signal generation. Inhibition was evaluated
at concentrations on the linear portion of the response curve.
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much of the sdAb had aggregated. It is important to consider that
unfolded/misfolded material and smaller aggregates may stay in
solution, so the lack of precipitation seen in the other samples does
not necessarily correlate with the functionality of the protein
remaining in solution, thus remaining binding activity was also
evaluated following the solubility determination.
To address the issues of poor solubility and thermal induced
aggregation, each protein was subjected to mutagenesis to lower
the pI of the sdAb creating the clones D12fneg, H1Wneg, and
C10neg (Fig. 1C) which reduced the calculated pI values to 6.72,
6.03, and 6.71, respectively. Positions for the negative mutations
were chosen by examining consensus sequences as well as looking
at the sequences of other sdAbs in the sequence families. CD
revealed that all three negative mutants showed close to 100%
ability to refold (bottom panels Fig. 2); the Tm of H1Wneg
decreased to 65 C, while D12fneg and C10neg were essentially
unchanged. The sdAbs D12f, H1W, C10, and their negatively
charged mutants were prepared at a concentration of 1 mg/mL
and incubated for 1 h at various temperatures followed by
determination of the concentration soluble protein remaining in
solution (Fig. 3A). The negative mutations dramatically decreased
the aggregation shown by H1W, with smaller improvements for
C10 and D12f.
Although the negatively charged proteins proved to be more
soluble and less prone to aggregation than the parental sdAbs it is
critical to ensure that they maintain functionality and are still
able to bind antigen after heating. Previously, we had observed
conventional antibodies that were still in solution after heating
but had lost all antigen binding ability [39]. Binding activity was
determined for sdAbs incubated for an hour at a concentration of
1 mg/mL at temperatures above their Tm (72 C for C10, C10neg,
H1W, and H1Wneg; 87 C for D12f and D12fneg). Functionality
was assayed by direct binding to ricin-coated magnetic micro-
spheres in a MagPlex-based assay (Fig. 3B). While C10neg was
shown to lose 30% more of its binding activity upon heating
when compared to C10, H1Wneg was shown to maintain more
Fig. 4. Aggregation resistance and activity of sdAbs after repeated heating/cooling cycles. (A) The sdAbs were prepared at 1 mg/mL, and cycled to 70 C for 30 min followed
by 25 C for 30 min. Following cycling, samples were centrifuged to pellet any precipitated protein, and the ﬁnal absorbance was measured. (B) The binding ability of the
negative mutants after cycling was assessed by SPR, measuring binding of 300 nM sdAb to ricin immobilized on a GLC sensor chip. The blue curve shows binding before
cycling, while the red measures binding after.
Fig. 5. Function of C10neg+ assessed by SPR before (black) and after (red) heat
cycling. The initial binding to ricin is shown for three concentrations of the sdAb.
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and D12fneg both maintained 100% binding activity even after
heating above their Tm.
In a different heat challenge, the proteins, D12fneg, H1Wneg,
and C10neg, at a concentration of 1 mg/mL, were subjected to
ten heat cycles during which they were taken up to 70 C for a
half-hour, then cooled to 25 C for a half-hour. Afterwards, the
samples were centrifuged to pellet any precipitated protein, and
the absorbance of samples that had been heat cycled was
compared to the unheated material (Fig. 4A). Additionally,
binding ability was assayed by SPR and showed that whereas
D12fneg had maintained 100% of its activity, C10neg and
H1Wneg retained only 33 and 20% of their initial binding
ability, respectively (Fig. 4B). It is necessary to note that 70 C is
below the Tm of D12fneg but above the Tm of C10neg and H1Wneg.
This suggested that even for sdAbs that can refold to retain activity
at high concentration and high temperature, maintenance of a
folded state is most advantageous.
These results suggested that addition of negative mutations did
little to enhance thermal stability, however these mutations were
highly effective at enhancing solubility at room temperature,
improving sdAb refolding upon denaturation, and facilitating
storage at high concentrations. Both the D12f and the
C10 precipitated well before they could be concentrated to
10 mg/mL, (5 mg/mL). However, all three negative mutants were
able to be concentrated to 10 mg/mL and stayed 100% in solution
at room temperature during the 11 day period during which the
solutions were monitored (not shown).3.4. Engineering extra cysteins to improve Tm
In an effort to raise the Tm of sdAbs that recognize each of the
3 epitopes on ricin to over 70 C, we introduced a pair of Cys placed
for formation of an extra disulﬁde between framework 2 and 3, in
the D12fneg, H1W, H1Wneg and C10neg clones (Fig. 1C). This
location was chosen as it had previously been demonstrated to
increase the stability and Tm of sdAbs [22–24,39,40]. Mutagenesis
resulted in the three clones: D12fneg+, H1Wneg+, and C10neg+.
The highest increase in Tmwas realized with C10neg+ with a Tm of
K.B. Turner et al. / Biotechnology Reports 6 (2015) 27–35 3378 C. The H1Wneg+ melting point was increased to 68 C; adding
the disulﬁde to the original H1W clone to produce H1W+ resulted
in a Tm of 75 C. The smallest increase was found with D12fneg+,
which offered only a minimal increase in Tm. As with the negative
mutants, the versions with the added pair of Cys were able to
regain 100% of their secondary structure after heating, as
determined by CD (not shown).
The D12fneg+ and C10neg+ were able to recognize ricin with
similar high afﬁnity as the parental sdAbs. They were subject to
thermal cycling as before, and both maintained near 100% of their
binding ability even after 10 cycles up to 70 C (C10neg+ is shown in
Fig. 5). Unfortunately, the increase in Tm that is found with the
introduction of an additional disulﬁde can come at the expense of0
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Fig. 6. Ampliﬁed bead based detection of ricin using thermal stabilized sdAbs. Shown on
plots of signal/background on the right to better visualize the response to low levels oafﬁnity [23]. The H1Wneg+ and H1W+ clones suffered signiﬁcant
loss of afﬁnity for ricin (Table 1).
3.5. Ricin detection using stabilized reagent
Three sdAbs with improved Tm (D12fneg, H1W, and C10neg)
were incorporated as sandwich pairs into MagPlex bead-based
assays for the detection of ricin (Fig. 6). Each of the sdAbs was used
as both a bead-immobilized capture and a biotinylated reporter. To
increase the signal intensities, the assays were ampliﬁed by
addition of Bt-goat anti-streptavdin following the ﬁrst addition of
SAPE, followed by a second incubation of SAPE. These steps were
found to increase the signal level by a factor of 5, and unlike1.0
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 the left side are plots of signal minus background, with the same data shown as log
f ricin. See Section 2.10 for assay details.
34 K.B. Turner et al. / Biotechnology Reports 6 (2015) 27–35earlier work where no improvement in signal to background was
achieved [36], a 5-fold increase in sensitivity versus unampliﬁed
assays was obtained (Supplemental Fig. 2). The D12fneg/Bt-C10neg
sdAb pair was demonstrated to be as effective as our previously
reported sdAbs for toxin detection. The ampliﬁcation step for these
negatively modiﬁed sdAbs was likely necessary to overcome the
reduced biotinylation level for the detection sdAb, as the
biotinylation reagent is amine directed.
It is important to ensure that biotinylating the sdAbs to produce
the reporter reagents does not negatively impact their Tm values.
Using biotinylated preparations of D12fneg and C10neg, we
performed CD analysis and conﬁrmed that the Tm of the
biotinylated and unbiotinylated sdAbs were identical (not shown).
4. Conclusions
We have demonstrated how a combination of thorough
evaluation of clonal variants available followed by consensus
sequence mutagenesis, negative mutations to improve solubility,
and Cys mutations to promote an additional disulﬁde can lead to
sdAbs with improved aggregation resistance and elevated Tms.
Decreasing aggregation and improving stability are properties that
may also be beneﬁcial for sdAbs developed as therapeutics [41].
We had previously shown that in addition to its potential use as a
detection reagent, the sdAb C8 was found to inhibit ricin’s
biological activity [26]. As D12 and C8 are in the same sequence
family, the improved anti-ricin sdAbs may also prove to have value
as therapeutic reagents.
This work demonstrated a road-map for improving the utility of
three sdAbs each of which binds a distinct epitope on ricin. In each
case we achieved a substantial increase in Tm over C8, H1, and D1,
the sdAbs that had previously been selected for the development of
ricin immunoassays.
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